A Multicenter Randomized Double-Blind Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional Therapies But Have Not Failed Biologic Therapy
Brief description of study
The objective of this study is to evaluate the efficacy and safety of upadacitinib compared to placebo as induction therapy in participants with moderately and severely active Crohn's disease (CD).
Clinical Study Identifier: s17-01252
ClinicalTrials.gov Identifier: NCT03345849
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.